Galenea Enters the RNAi Drugs Arena With Technology from MIT Researcher | GenomeWeb

When MIT researcher Jianzhu Chen spoke with RNAi News late last year about his work on an siRNA-based treatment for the influenza virus, he mentioned that he expected to find a commercial partner to help him continue development (see RNAi News, 10/31/2003).

As it turns out, he decided that developing the product at his own company made better sense, and Chen is now one of the co-founders of Galenea.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.